Spotlight on Gynecology/Obstetrics

Credits: 0.50 CNE
Expert Insights: Patient and Nurse Perspectives on the Use of PARP Inhibitors for Ovarian Cancer: Strategies for Maximizing Patient Outcomes
Paula Anastasia, RN, MN, AOCN
University of Nebraska Medical Center

Expert Insights: Patient and Nurse Perspectives on the Use of PARP Inhibitors for Ovarian Cancer: Strategies for Maximizing Patient Outcomes

Start

Activity Details

Free CNE
0.5 Contact Hours
Released: September 11, 2019
Expires: September 11, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, College of Nursing Continuing Nursing Education

Learning Objectives

After completing this activity, participants should be better able to:

  • Identify patients with ovarian cancer who are most appropriate to receive treatment with PARP inhibitors
  • Evaluate recent clinical updates and novel indications of PARP inhibitors for the treatment of patients with ovarian cancer
  • Discuss approaches for PARP inhibitors that incorporate patient perspectives regarding maintenance therapy
  • Assess nursing interventions and treatment management strategies to prevent and mitigate therapeutic-related adverse events, including the utilization of dose modification guidelines

Activity Description

Expert Insights captures a stimulating and informative conversation about patient selection for PARP inhibitor therapy, a review of clinical data, and strategies for managing common adverse events that occur with PARP inhibitor therapy for ovarian cancer.

Statement of Educational Need

Because of the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, nurses are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, nurses treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications into practice when they become available, in consideration of patient needs and preferences.

Faculty

Paula Anastasia, RN, MN, AOCN - Moderator
Gynecologic Oncology, Clinical Nurse Specialist
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California


Kimberly Halla, MSN, FNP-C
Gynecologic Oncology, Nurse Practitioner
Arizona Oncology
Phoenix, Arizona


Conflict of Interest Policy/Disclosure Statement

All planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education (UNMC CON CNE) are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
 
The following speakers and planning committee members listed below have stated they have no financial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity.

  • Paula Anastasia, RN, MN, AOCN
  • Dru S. Dace, PhD
  • Kimberly Halla, MSN, FNP-C
  • Heidi Keeler, PhD, RN
  • Renee Paulin, MSN, RN, CWOCN
  • Kraig Steubing, BS

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

The opinions expressed in the educational activity do not necessarily represent the views of UNMC CON CNE and Bio Ascend, LLC.

Accreditation Statement and Joint Providership

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

This activity is provided for 0.5 contact hours under ANCC criteria.

UNMC CON CNE has been awarded Accreditation with Distinction, the highest recognition awarded by the ANCC’s Accreditation Program. This distinction is valid through 2020.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ANCC’s Commission on Accreditation through the joint providership of UNMC CON CNE (provider) and Bio Ascend, LLC.

Accredited status as a provider of continuing nursing education refers only to UNMC CON CNE continuing education activities, and does not imply UNMC or ANCC’s Commission on Accreditation endorsement of any commercial supporters.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 30 minutes. In order to receive contact hours, you must complete the following prior to the activity expiration date of September 11, 2020: 1) Read the continuing nursing education disclosures and disclaimers related to this activity; 2) Complete the pre-test; 3) Watch the presentation; 4) Successfully complete the post-test with a score of 66% (2/3) or better; 5) Complete the contact information and evaluation forms. Your certificate of completion will be available to download or print upon successful completion of the post-test and submission of your contact information and evaluation.

Statement of Commercial Support

The UNMC College of Nursing CNE Program and Bio Ascend thank the following companies for their generous support of this program in the form of educational grants: AstraZeneca and Tesaro, Inc.

Activity Details

Free CNE
0.5 Contact Hours
Released: September 11, 2019
Expires: September 11, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, College of Nursing Continuing Nursing Education

Learning Objectives

After completing this activity, participants should be better able to:

  • Identify patients with ovarian cancer who are most appropriate to receive treatment with PARP inhibitors
  • Evaluate recent clinical updates and novel indications of PARP inhibitors for the treatment of patients with ovarian cancer
  • Discuss approaches for PARP inhibitors that incorporate patient perspectives regarding maintenance therapy
  • Assess nursing interventions and treatment management strategies to prevent and mitigate therapeutic-related adverse events, including the utilization of dose modification guidelines

Activity Description

Expert Insights captures a stimulating and informative conversation about patient selection for PARP inhibitor therapy, a review of clinical data, and strategies for managing common adverse events that occur with PARP inhibitor therapy for ovarian cancer.

Statement of Educational Need

Because of the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, nurses are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, nurses treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications into practice when they become available, in consideration of patient needs and preferences.

Faculty

Paula Anastasia, RN, MN, AOCN - Moderator
Gynecologic Oncology, Clinical Nurse Specialist
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California


Kimberly Halla, MSN, FNP-C
Gynecologic Oncology, Nurse Practitioner
Arizona Oncology
Phoenix, Arizona


Conflict of Interest Policy/Disclosure Statement

All planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education (UNMC CON CNE) are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
 
The following speakers and planning committee members listed below have stated they have no financial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity.

  • Paula Anastasia, RN, MN, AOCN
  • Dru S. Dace, PhD
  • Kimberly Halla, MSN, FNP-C
  • Heidi Keeler, PhD, RN
  • Renee Paulin, MSN, RN, CWOCN
  • Kraig Steubing, BS

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

The opinions expressed in the educational activity do not necessarily represent the views of UNMC CON CNE and Bio Ascend, LLC.

Accreditation Statement and Joint Providership

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

This activity is provided for 0.5 contact hours under ANCC criteria.

UNMC CON CNE has been awarded Accreditation with Distinction, the highest recognition awarded by the ANCC’s Accreditation Program. This distinction is valid through 2020.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ANCC’s Commission on Accreditation through the joint providership of UNMC CON CNE (provider) and Bio Ascend, LLC.

Accredited status as a provider of continuing nursing education refers only to UNMC CON CNE continuing education activities, and does not imply UNMC or ANCC’s Commission on Accreditation endorsement of any commercial supporters.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 30 minutes. In order to receive contact hours, you must complete the following prior to the activity expiration date of September 11, 2020: 1) Read the continuing nursing education disclosures and disclaimers related to this activity; 2) Complete the pre-test; 3) Watch the presentation; 4) Successfully complete the post-test with a score of 66% (2/3) or better; 5) Complete the contact information and evaluation forms. Your certificate of completion will be available to download or print upon successful completion of the post-test and submission of your contact information and evaluation.

Statement of Commercial Support

The UNMC College of Nursing CNE Program and Bio Ascend thank the following companies for their generous support of this program in the form of educational grants: AstraZeneca and Tesaro, Inc.

Gynecology/Obstetrics Presentations

0.50 CNE
University of Nebraska Medical Center
Expert Insights: Patient and Nurse Perspectives on the Use of PARP Inhibitors for Ovarian Cancer: Strategies for Maximizing Patient Outcomes

Expert Insights: Patient and Nurse Perspectives on the Use of PARP Inhibitors for Ovarian Cancer: Strategies for Maximizing Patient Outcomes

Start

Activity Details

Free CNE
0.5 Contact Hours
Released: September 11, 2019
Expires: September 11, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, College of Nursing Continuing Nursing Education

Learning Objectives

After completing this activity, participants should be better able to:

  • Identify patients with ovarian cancer who are most appropriate to receive treatment with PARP inhibitors
  • Evaluate recent clinical updates and novel indications of PARP inhibitors for the treatment of patients with ovarian cancer
  • Discuss approaches for PARP inhibitors that incorporate patient perspectives regarding maintenance therapy
  • Assess nursing interventions and treatment management strategies to prevent and mitigate therapeutic-related adverse events, including the utilization of dose modification guidelines

Activity Description

Expert Insights captures a stimulating and informative conversation about patient selection for PARP inhibitor therapy, a review of clinical data, and strategies for managing common adverse events that occur with PARP inhibitor therapy for ovarian cancer.

Statement of Educational Need

Because of the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, nurses are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, nurses treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications into practice when they become available, in consideration of patient needs and preferences.

Faculty

Paula Anastasia, RN, MN, AOCN - Moderator
Gynecologic Oncology, Clinical Nurse Specialist
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California


Kimberly Halla, MSN, FNP-C
Gynecologic Oncology, Nurse Practitioner
Arizona Oncology
Phoenix, Arizona


Conflict of Interest Policy/Disclosure Statement

All planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education (UNMC CON CNE) are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
 
The following speakers and planning committee members listed below have stated they have no financial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity.

  • Paula Anastasia, RN, MN, AOCN
  • Dru S. Dace, PhD
  • Kimberly Halla, MSN, FNP-C
  • Heidi Keeler, PhD, RN
  • Renee Paulin, MSN, RN, CWOCN
  • Kraig Steubing, BS

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

The opinions expressed in the educational activity do not necessarily represent the views of UNMC CON CNE and Bio Ascend, LLC.

Accreditation Statement and Joint Providership

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

This activity is provided for 0.5 contact hours under ANCC criteria.

UNMC CON CNE has been awarded Accreditation with Distinction, the highest recognition awarded by the ANCC’s Accreditation Program. This distinction is valid through 2020.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ANCC’s Commission on Accreditation through the joint providership of UNMC CON CNE (provider) and Bio Ascend, LLC.

Accredited status as a provider of continuing nursing education refers only to UNMC CON CNE continuing education activities, and does not imply UNMC or ANCC’s Commission on Accreditation endorsement of any commercial supporters.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 30 minutes. In order to receive contact hours, you must complete the following prior to the activity expiration date of September 11, 2020: 1) Read the continuing nursing education disclosures and disclaimers related to this activity; 2) Complete the pre-test; 3) Watch the presentation; 4) Successfully complete the post-test with a score of 66% (2/3) or better; 5) Complete the contact information and evaluation forms. Your certificate of completion will be available to download or print upon successful completion of the post-test and submission of your contact information and evaluation.

Statement of Commercial Support

The UNMC College of Nursing CNE Program and Bio Ascend thank the following companies for their generous support of this program in the form of educational grants: AstraZeneca and Tesaro, Inc.

Activity Details

Free CNE
0.5 Contact Hours
Released: September 11, 2019
Expires: September 11, 2020
30 minutes to complete

Accredited By

The University of Nebraska Medical Center, College of Nursing Continuing Nursing Education

Learning Objectives

After completing this activity, participants should be better able to:

  • Identify patients with ovarian cancer who are most appropriate to receive treatment with PARP inhibitors
  • Evaluate recent clinical updates and novel indications of PARP inhibitors for the treatment of patients with ovarian cancer
  • Discuss approaches for PARP inhibitors that incorporate patient perspectives regarding maintenance therapy
  • Assess nursing interventions and treatment management strategies to prevent and mitigate therapeutic-related adverse events, including the utilization of dose modification guidelines

Activity Description

Expert Insights captures a stimulating and informative conversation about patient selection for PARP inhibitor therapy, a review of clinical data, and strategies for managing common adverse events that occur with PARP inhibitor therapy for ovarian cancer.

Statement of Educational Need

Because of the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, nurses are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, nurses treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications into practice when they become available, in consideration of patient needs and preferences.

Faculty

Paula Anastasia, RN, MN, AOCN - Moderator
Gynecologic Oncology, Clinical Nurse Specialist
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California


Kimberly Halla, MSN, FNP-C
Gynecologic Oncology, Nurse Practitioner
Arizona Oncology
Phoenix, Arizona


Conflict of Interest Policy/Disclosure Statement

All planners and faculty participating in continuing education activities provided by the University of Nebraska Medical Center, College of Nursing Continuing Nursing Education (UNMC CON CNE) are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
 
The following speakers and planning committee members listed below have stated they have no financial relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporter of this activity.

  • Paula Anastasia, RN, MN, AOCN
  • Dru S. Dace, PhD
  • Kimberly Halla, MSN, FNP-C
  • Heidi Keeler, PhD, RN
  • Renee Paulin, MSN, RN, CWOCN
  • Kraig Steubing, BS

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

The opinions expressed in the educational activity do not necessarily represent the views of UNMC CON CNE and Bio Ascend, LLC.

Accreditation Statement and Joint Providership

The University of Nebraska Medical Center College of Nursing Continuing Nursing Education (UNMC CON CNE) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

This activity is provided for 0.5 contact hours under ANCC criteria.

UNMC CON CNE has been awarded Accreditation with Distinction, the highest recognition awarded by the ANCC’s Accreditation Program. This distinction is valid through 2020.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ANCC’s Commission on Accreditation through the joint providership of UNMC CON CNE (provider) and Bio Ascend, LLC.

Accredited status as a provider of continuing nursing education refers only to UNMC CON CNE continuing education activities, and does not imply UNMC or ANCC’s Commission on Accreditation endorsement of any commercial supporters.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. The estimated time to complete this activity is 30 minutes. In order to receive contact hours, you must complete the following prior to the activity expiration date of September 11, 2020: 1) Read the continuing nursing education disclosures and disclaimers related to this activity; 2) Complete the pre-test; 3) Watch the presentation; 4) Successfully complete the post-test with a score of 66% (2/3) or better; 5) Complete the contact information and evaluation forms. Your certificate of completion will be available to download or print upon successful completion of the post-test and submission of your contact information and evaluation.

Statement of Commercial Support

The UNMC College of Nursing CNE Program and Bio Ascend thank the following companies for their generous support of this program in the form of educational grants: AstraZeneca and Tesaro, Inc.

0.25 CME
AXIS
Expert Answers to Common Questions for Optimizing the Use of CDK4 and CDK6 Inhibitors for Metastatic Breast Cancer

Expert Answers to Common Questions for Optimizing the Use of CDK4 and CDK6 Inhibitors for Metastatic Breast Cancer

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: March 26, 2019
Expires: March 25, 2020
15 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat or manage advanced or metastatic breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe the mechanism of action of cyclin-dependent kinase 4/6 inhibitors, including differences among available and emerging agents
  • Compare and contrast the dosing and efficacy of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer
  • Select the appropriate cyclin-dependent kinase 4/6 inhibitor for patients according to their efficacy, safety, and patient characteristics
  • Identify common toxicities of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer, including gastrointestinal toxicity and neutropenia

Activity Description

Recently, there have been significant advances in the development of agents that target critical pathways involved in resistance to endocrine therapy in HR-positive/HER2-negative breast cancer, such as cyclin-dependent kinase (CDK) 4/6 inhibitors,  palbociclib, abemaciclib, and ribociclib.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on CDK4/6 inhibitors for the treatment of advanced HR-positive/HER2-negative breast cancer.

Statement of Educational Need

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the use of CDK4 and CDK6 inhibitors for the treatment of HR-positive/HER2-negative advanced or metastatic breast cancer so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices with their patients.

Faculty

Adam M. Brufsky, MD, PhD, FACP
Professor of Medicine / Associate Chief, Hematology-Oncology / Associate Director, Translational Research
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Adam M. Brufsky, MD, PhD, FACP
  • Adam M. Brufsky, MD, PhD, FACP, reported a financial interest/relationship or affiliation in the form of: Received consulting fees from Lilly USA; Novartis Pharmaceuticals Corp; Pfizer, Inc; Amgen, Inc; and AstraZeneca Pharmaceuticals LP.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: March 26, 2019
Expires: March 25, 2020
15 minutes to complete

Provided by

This educational activity is provided by

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat or manage advanced or metastatic breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe the mechanism of action of cyclin-dependent kinase 4/6 inhibitors, including differences among available and emerging agents
  • Compare and contrast the dosing and efficacy of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer
  • Select the appropriate cyclin-dependent kinase 4/6 inhibitor for patients according to their efficacy, safety, and patient characteristics
  • Identify common toxicities of cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer, including gastrointestinal toxicity and neutropenia

Activity Description

Recently, there have been significant advances in the development of agents that target critical pathways involved in resistance to endocrine therapy in HR-positive/HER2-negative breast cancer, such as cyclin-dependent kinase (CDK) 4/6 inhibitors,  palbociclib, abemaciclib, and ribociclib.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on CDK4/6 inhibitors for the treatment of advanced HR-positive/HER2-negative breast cancer.

Statement of Educational Need

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the use of CDK4 and CDK6 inhibitors for the treatment of HR-positive/HER2-negative advanced or metastatic breast cancer so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices with their patients.

Faculty

Adam M. Brufsky, MD, PhD, FACP
Professor of Medicine / Associate Chief, Hematology-Oncology / Associate Director, Translational Research
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Adam M. Brufsky, MD, PhD, FACP
  • Adam M. Brufsky, MD, PhD, FACP, reported a financial interest/relationship or affiliation in the form of: Received consulting fees from Lilly USA; Novartis Pharmaceuticals Corp; Pfizer, Inc; Amgen, Inc; and AstraZeneca Pharmaceuticals LP.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation for Physicians

AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CNE
Postgraduate Institute for Medicine
Updates in HCV Screening and Treatment: Key Issues Impacting OB/GYN Practice

Updates in HCV Screening and Treatment: Key Issues Impacting OB/GYN Practice

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 ANCC Contact Hour
Released: February 8, 2019
Expires: February 8, 2020
1 hour to complete

Jointly Provided By

Postgraduate Institute for Medicine and Integritas Communications

Target Audience

This educational activity is intended to educate obstetrics/gynecology (OB/GYN) physicians, physician assistants, nurse practitioners, and nurse midwives on appropriate hepatitis C virus (HCV) screening, testing, and referral practices for their patients.

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Provide proactive hepatitis C virus (HCV) screening and confirmatory testing for obstetrics/gynecology (OB/GYN) patients per guidelines from the American Association for the Study of Liver Disease and the Society for Maternal-Fetal Medicine
  • Counsel patients on the implications of HCV infection, efficacy and safety of current direct-acting antiviral treatment regimens for chronic HCV infection, and behavioral risk reduction
  • Coordinate appropriate referrals and multidisciplinary care for HCV-infected women presenting in OB/GYN practices

Activity Description

This activity presents practical information for OB/GYNs on HCV screening, confirmatory testing, patient education, and counseling strategies for use within the real-world clinical context of their practice. While HCV impacts women across diverse age groups and demographics, pregnancy raises additional considerations and risks for the HCV-infected mother and her unborn child, including mother-to-child transmission of the virus, for which faculty share recommendations and management insights.

Statement of Educational Need

This educational activity is designed to better prepare OB/GYNs to identify patients who should be screened for HCV based on relevant professional society recommendations, appropriately link patients to care, and manage pregnancies of women who have HCV. Expert faculty will provide practical information on HCV screening, confirmatory testing, patient education, and counseling strategies for use within the real-world clinical context of OB/GYN practice. Although HCV affects women across diverse age groups and demographics, pregnancy raises additional considerations and risks for the HCV-infected mother and her unborn child, including mother-to-child-transmission of the virus, for which faculty will share recommendations and management insights.

Agenda

Introduction
Why Should OB/GYNs Be Concerned About HCV?
The OB/GYN’s Role in HCV Care
Conclusion

Faculty

Nancy S. Reau, MD
The Richard B. Capps Chair of Hepatology
Professor, Department of Internal Medicine
Division of Digestive Diseases and Nutrition
Rush Medical College
Chief, Section of Hepatology
Associate Director of Organ Transplantation
Rush University Medical Center
Chicago, Illinois


Joanne L. Stone, MD, MSHCDL
Director, Maternal Fetal Medicine Mount Sinai Health System
Fellowship Director, Maternal Fetal Medicine Mount Sinai Hospital
Professor, Obstetrics, Gynecology and Reproductive Sciences
Icahn School of Medicine at Mount Sinai
New York, New York


Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Nancy S. Reau, MD      
Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Merck & Co., Inc.
Contracted Research: GENFIT SA, Intercept Pharmaceuticals, Inc., Shire plc

Joanne L. Stone, MD, MSHCDL
No financial relationships to disclose

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Instructions to Receive Credit

A statement of credit will be issued immediately upon receipt of a completed activity evaluation form.

Instructions for Receiving Credit

In order to claim credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians, NPs, PAs, and RNs who achieves a grade of 75% or better on the Post-Activity Test and who completes the Evaluation will receive a CME/CE Certificate.
  6. All other participant who achieves a grade of 75% or better on the Post-Activity Test Questions and who completes the Evaluation will receive a Certificate of Participation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions about the Activity

If you have questions regarding the receipt of your emailed certificate, please contact PIM via email at inquiries@pimed.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit
1.0 ANCC Contact Hour
Released: February 8, 2019
Expires: February 8, 2020
1 hour to complete

Jointly Provided By

Postgraduate Institute for Medicine and Integritas Communications

Target Audience

This educational activity is intended to educate obstetrics/gynecology (OB/GYN) physicians, physician assistants, nurse practitioners, and nurse midwives on appropriate hepatitis C virus (HCV) screening, testing, and referral practices for their patients.

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Provide proactive hepatitis C virus (HCV) screening and confirmatory testing for obstetrics/gynecology (OB/GYN) patients per guidelines from the American Association for the Study of Liver Disease and the Society for Maternal-Fetal Medicine
  • Counsel patients on the implications of HCV infection, efficacy and safety of current direct-acting antiviral treatment regimens for chronic HCV infection, and behavioral risk reduction
  • Coordinate appropriate referrals and multidisciplinary care for HCV-infected women presenting in OB/GYN practices

Activity Description

This activity presents practical information for OB/GYNs on HCV screening, confirmatory testing, patient education, and counseling strategies for use within the real-world clinical context of their practice. While HCV impacts women across diverse age groups and demographics, pregnancy raises additional considerations and risks for the HCV-infected mother and her unborn child, including mother-to-child transmission of the virus, for which faculty share recommendations and management insights.

Statement of Educational Need

This educational activity is designed to better prepare OB/GYNs to identify patients who should be screened for HCV based on relevant professional society recommendations, appropriately link patients to care, and manage pregnancies of women who have HCV. Expert faculty will provide practical information on HCV screening, confirmatory testing, patient education, and counseling strategies for use within the real-world clinical context of OB/GYN practice. Although HCV affects women across diverse age groups and demographics, pregnancy raises additional considerations and risks for the HCV-infected mother and her unborn child, including mother-to-child-transmission of the virus, for which faculty will share recommendations and management insights.

Agenda

Introduction
Why Should OB/GYNs Be Concerned About HCV?
The OB/GYN’s Role in HCV Care
Conclusion

Faculty

Nancy S. Reau, MD
The Richard B. Capps Chair of Hepatology
Professor, Department of Internal Medicine
Division of Digestive Diseases and Nutrition
Rush Medical College
Chief, Section of Hepatology
Associate Director of Organ Transplantation
Rush University Medical Center
Chicago, Illinois


Joanne L. Stone, MD, MSHCDL
Director, Maternal Fetal Medicine Mount Sinai Health System
Fellowship Director, Maternal Fetal Medicine Mount Sinai Hospital
Professor, Obstetrics, Gynecology and Reproductive Sciences
Icahn School of Medicine at Mount Sinai
New York, New York


Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Nancy S. Reau, MD      
Consulting Fees: AbbVie Inc., Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Merck & Co., Inc.
Contracted Research: GENFIT SA, Intercept Pharmaceuticals, Inc., Shire plc

Joanne L. Stone, MD, MSHCDL
No financial relationships to disclose

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Instructions to Receive Credit

A statement of credit will be issued immediately upon receipt of a completed activity evaluation form.

Instructions for Receiving Credit

In order to claim credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians, NPs, PAs, and RNs who achieves a grade of 75% or better on the Post-Activity Test and who completes the Evaluation will receive a CME/CE Certificate.
  6. All other participant who achieves a grade of 75% or better on the Post-Activity Test Questions and who completes the Evaluation will receive a Certificate of Participation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions about the Activity

If you have questions regarding the receipt of your emailed certificate, please contact PIM via email at inquiries@pimed.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / MOC / CNE
The France Foundation
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring

PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring

Start

Activity Details

Free CME/MOC/CNE
0.25 AMA PRA Category 1 Credits™/
MOC Points
0.25 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
15 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This case-based webinar includes implications of genetic testing for treatment decisions, and reviews the safety and efficacy of FDA-approved PARP inhibitors for patients with metastatic or advanced breast cancer with germline BRCA mutations.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Ruth M. O’Regan, MD
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

The following faculty report that they have relevant financial relationships to disclose:
  • Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.


Jennie Petruney, ANP
Nurse Practitioner
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

The following faculty report that they have no relevant financial relationships to disclose:
  • Jennie Petruney, ANP

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring can earn a maximum of 0.25 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)  

  • Coordination of Care – 0.25 points
  • Diagnosis and Staging – 0.25 points
  • Treatment – 0.25 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/MOC/CNE
0.25 AMA PRA Category 1 Credits™/
MOC Points
0.25 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
15 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This case-based webinar includes implications of genetic testing for treatment decisions, and reviews the safety and efficacy of FDA-approved PARP inhibitors for patients with metastatic or advanced breast cancer with germline BRCA mutations.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Ruth M. O’Regan, MD
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

The following faculty report that they have relevant financial relationships to disclose:
  • Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.


Jennie Petruney, ANP
Nurse Practitioner
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina

The following faculty report that they have no relevant financial relationships to disclose:
  • Jennie Petruney, ANP

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Understanding and Applying PARP Inhibitor Data to Selection and Monitoring can earn a maximum of 0.25 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)  

  • Coordination of Care – 0.25 points
  • Diagnosis and Staging – 0.25 points
  • Treatment – 0.25 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / MOC / CNE
The France Foundation
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision

PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision

Start

Activity Details

Free CME/MOC/CNE
0.50 AMA PRA Category 1 Credits™/
MOC Points
0.50 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
30 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This webinar provides an overview of PARP inhibitor therapy for patients with breast cancer, including use as single-agent therapy, and ongoing studies evaluating PARP inhibitors in combination with chemotherapy and immunotherapy for this patient population.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Ruth M. O’Regan, MD
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

The following faculty report that they have relevant financial relationships to disclose:
  • Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.


Carol K. Tweed, MD
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland

The following faculty report that they have relevant financial relationships to disclose:
  • Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision can earn a maximum of 0.50 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)  

  • Diagnosis and Staging – 0.50 points
  • Treatment – 0.50 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/MOC/CNE
0.50 AMA PRA Category 1 Credits™/
MOC Points
0.50 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
30 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This webinar provides an overview of PARP inhibitor therapy for patients with breast cancer, including use as single-agent therapy, and ongoing studies evaluating PARP inhibitors in combination with chemotherapy and immunotherapy for this patient population.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Ruth M. O’Regan, MD
Associate Director, Clinical Research
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

The following faculty report that they have relevant financial relationships to disclose:
  • Ruth O’Regan, MD, has done contract research for Eisai, Novartis and Pfizer, Inc. Dr. O’Regan has served as an advisor for Genentech, Immunogenics, Lilly, MacroGenics, Novartis, Pfizer, Inc. and Puma.


Carol K. Tweed, MD
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland

The following faculty report that they have relevant financial relationships to disclose:
  • Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Future Vision can earn a maximum of 0.50 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON)  

  • Diagnosis and Staging – 0.50 points
  • Treatment – 0.50 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME / MOC / CNE
The France Foundation
PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use

PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use

Start

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credits™/
MOC Points
0.75 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
45 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This case-based webinar reviews criteria for BRCA1/2 testing, the importance of obtaining family history for patients with cancer, interpretation of genetic testing results for patients with metastatic breast cancer and their families, and ways to access genetic services.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Joy Larsen Haidle, MS, CGC
Genetic Counselor
North Memorial Health Cancer Center
Robbinsdale, Minnesota

The following faculty report that they have no relevant financial relationships to disclose:
  • Joy Larsen Haidle, MS, CGC


Carol K. Tweed, MD
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland

The following faculty report that they have relevant financial relationships to disclose:
  • Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use can earn a maximum of 0.75 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON).

  • Diagnosis and Staging – 0.75 points 
  • Treatment – 0.75 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/MOC/CNE
0.75 AMA PRA Category 1 Credits™/
MOC Points
0.75 Contact Hour(s)
Released: December 20, 2018
Expires: December 19, 2019
45 minutes to complete

Jointly Provided by

Target Audience

This educational initiative is intended for oncologists, nurse practitioners, and nurses who manage patients with metastatic breast cancer (MBC).

Learning Objectives

  • Use BRCA and other key genomic tests in an appropriate and timely manner for patients with MBC
  • Interpret the results of genomic testing accurately, including working effectively with genetic counselors
  • Recommend PARP inhibitor use appropriately on the basis of key data/characteristics and recommendations in advanced breast cancer (BC)
  • Discuss results of genetic testing and implications of PARP inhibitor therapy with patients and families

Activity Description

This case-based webinar reviews criteria for BRCA1/2 testing, the importance of obtaining family history for patients with cancer, interpretation of genetic testing results for patients with metastatic breast cancer and their families, and ways to access genetic services.

Statement of Educational Need

MBC has a five-year survival rate of only 26%, and stands in stark contrast to localized and regionally advanced diseases. Those have a five-year survival rate of 99% and 85%, respectively, thanks to therapy improvements over several decades. Oncology clinicians continue to face several challenges in optimizing personalized, targeted treatment for MBC in a climate where data on biomarkers and evolving treatment strategies continue to emerge at a rapid pace.

Faculty

Joy Larsen Haidle, MS, CGC
Joy Larsen Haidle, MS, CGC
Genetic Counselor
North Memorial Health Cancer Center
Robbinsdale, Minnesota

The following faculty report that they have no relevant financial relationships to disclose:
  • Joy Larsen Haidle, MS, CGC


Carol K. Tweed, MD
Medical Oncologist
Anne Arundel Medical Center
Annapolis, Maryland

The following faculty report that they have relevant financial relationships to disclose:
  • Carol K. Tweed, MD, has served on an advisory board for AstraZeneca. She has served on a Non-CE speakers bureau for Genomic Health.

MOC Reviewers

Theodore Bruno, MD
Chief Medical Officer
The France Foundation
Old Lyme, Connecticut

The following faculty report that they have relevant financial relationships to disclose:
  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.


Patrick Thomas Grogan, MD, PhD
Hematology/Oncology Fellow
University of Wisconsin Hospital and Clinics
Department of Medicine
Division of Hematology/Oncology
Madison, Wisconsin

The following faculty report that they have no relevant financial relationships to disclose:
  • Patrick Thomas Grogan, MD, PhD

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the Association of Community Cancer Centers (ACCC) and the Oncology Nursing Society (ONS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ACCC and ONS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACCC and ONS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACCC and ONS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of TFF, ACCC and ONS. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Participants in PARP Inhibitors: Advancing Personalized Medicine for Patients with Metastatic Breast Cancer – Appropriate Genetic Testing and Implications for Targeted Therapy Use can earn a maximum of 0.75 contact hours of CNE upon the successful completion of this continuing education activity. No partial credit will be given. Participants must view sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit. NOTE: It is not required to complete all three parts of the series to claim your CNE certificate for one of the parts.

ANCC

ILNA Information 
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. CNE sessions have been classified into the following ILNA categories for all certification renewals (OCN, BMTCN, AOCNP, AOCNS, CBCN, CPHON).

  • Diagnosis and Staging – 0.75 points 
  • Treatment – 0.75 points

Method of Participation / How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 50% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from Pfizer, Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

TFF, ACCC and ONS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACCC and ONS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.